Tamper-Resistant PSE Formulation To Prevent The Illicit Production Of Methamphetamine

The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.



$73 BILLION BY 2021


North America was the largest region in the respiratory diseases drugs market in 2017, accounting for half of the market share. This was mainly due to high number of patients with respiratory diseases, more people covered under medical insurance programs and higher pricing of medications in the USA.


Order the report at https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2018


The chart below shows the year-on-year growth of the global respiratory drugs market during 2017 – 2021


According to The Business Research Company’s Consultant, Nitin Gianchandani, pharmaceutical companies are focusing on nasal remedies owing to growing consumer demand for these products. Nasal remedies for cold include sprays, drops or inhalers such as nasal spray, saline spray, steroid spray, antihistamine spray, and nose drops. These remedies work faster than traditional drugs and these products are generally sold over-the-counter (OTC).


Download a sample of the report at:



GlaxoSmithKline was the largest company in the respiratory disorder drugs market in 2017, generating revenues of $13.2 billion for the financial year 2016. The company’s strategy involves increasing investments in R&D to drive discovery and development in respiratory diseases drugs. In 2016, GSK filed Closed Triple therapy for chronic obstructive pulmonary disease (COPD) for regulatory approval in Europe and the US. The company has also in-licensed anti-IL33R antibody for severe asthma, and danirixin is into phase IIb clinical development for treating patients with COPD.


The respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®.


Respiratory Diseases Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.


About The Business Research Company:


Visit TheBusinessResearchCompany.com, mail [email protected] or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.


The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.


It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.


The Business Research Company’s management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations.


Contact Information:


The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]


Leave a Reply